Klivira
Request demo

Navigating Anthem (Elevance Health) Mavenclad Prior Authorization

Successfully managing Anthem (Elevance Health) Mavenclad prior authorization is critical for timely patient access to this essential multiple sclerosis therapy. Klivira automates the complex workflows involved.

For revenue cycle and prior authorization teams, the administrative burden of specialty drug PAs, such as for Mavenclad, can lead to delays and denials. Understanding Anthem's specific requirements, submission channels, and policy nuances is key to optimizing approval rates and patient care.

Understanding Mavenclad PA with Anthem (Elevance Health)

Mavenclad (cladribine) is an oral specialty medication indicated for relapsing forms of multiple sclerosis (RMS), frequently requiring prior authorization across commercial, Medicare Advantage, and Medicaid managed care plans under Anthem. As a high-cost, high-impact therapy, Anthem-licensed plans implement rigorous utilization management policies to ensure medical necessity and appropriate use for this patient cohort.

Anthem Prior Authorization Submission Channels for Mavenclad

For Mavenclad, an oral specialty drug, prior authorization typically routes through CarelonRx, Elevance Health's in-house Pharmacy Benefit Manager (PBM). Prescriber-initiated pharmacy benefit PAs can be submitted via industry-standard ePA platforms such as CoverMyMeds and Surescripts, which integrate with CarelonRx's systems. For medical benefit specialty drugs, submissions are often directed through Availity Essentials or X12 278 transactions via clearinghouses.

Accessing Anthem's Utilization Management Policies for Specialty Drugs

Anthem operating companies publish medical policies and clinical utilization management guidelines through provider portals, accessible via Availity. For specialty drugs like Mavenclad, these policies detail specific medical necessity criteria, step therapy requirements, and quantity limits. It is essential to consult the state-specific Anthem plan's medical policy library for the most current and applicable criteria, referencing the specific policy number and effective date.

Prior Authorization Turnaround Times and Regulatory Compliance

Prior authorization turnaround times for Mavenclad with Anthem-licensed plans are governed by state insurance regulations for commercial lines and by federal mandates for Medicare Advantage and Medicaid managed care. Anthem's MA and Medicaid plans, including those under the Wellpoint brand, are impacted by CMS-0057-F, which establishes specific 72-hour standard and 24-hour expedited decision timeframes on a phased compliance timeline. Klivira helps track these timeframes to support compliance.

Common Denial Reasons and Appeal Pathways for Mavenclad

Denials for Mavenclad prior authorizations from Anthem may arise from reasons such as insufficient documentation of medical necessity, failure to complete required step therapy, or non-formulary status for the specific plan. Anthem returns denial reasons via X12 277/835 transactions and through Availity status updates. Appeals for standard medical or pharmacy PAs follow the Anthem operating-company appeals process documented in their provider manual, with peer-to-peer review options available.

Klivira's Role in Streamlining Anthem Mavenclad PAs

Klivira automates the multi-channel submission process for Anthem (Elevance Health) Mavenclad prior authorizations, integrating directly with EMRs and payer portals. Our platform streamlines the collection of clinical documentation, tracks policy updates, and facilitates electronic submission through supported channels like Availity and ePA partners, reducing administrative burden and accelerating decision times for your organization.

Frequently asked questions

Which Anthem entity manages Mavenclad prior authorizations?

For most Anthem-licensed plans, Mavenclad (cladribine) prior authorizations for the pharmacy benefit are managed by CarelonRx, Elevance Health's in-house PBM. Submissions typically route through CarelonRx's provider PA system or industry ePA platforms like CoverMyMeds and Surescripts.

How can I access Anthem's clinical criteria for Mavenclad?

Anthem operating companies publish their medical policies and clinical utilization management guidelines through provider sites, accessible via Availity. It is crucial to consult the specific state-licensed Anthem plan's policy index for the most current medical necessity criteria for Mavenclad, including any step therapy requirements.

Does Anthem support electronic prior authorization (ePA) for Mavenclad?

Yes, for Mavenclad under the pharmacy benefit, Anthem's PBM, CarelonRx, supports electronic prior authorization (ePA) submissions through established platforms such as CoverMyMeds and Surescripts. Klivira integrates with these pathways to facilitate efficient electronic submissions and reduce manual effort.

What are common reasons for Mavenclad PA denials by Anthem?

Common denial reasons for Mavenclad prior authorizations from Anthem include insufficient clinical documentation to support medical necessity, failure to meet required step therapy, or if the drug is deemed non-formulary for the specific plan. Denials are communicated via X12 277/835 transactions or Availity status updates.

How does Klivira help with Mavenclad PAs for Anthem?

Klivira streamlines Anthem Mavenclad prior authorizations by automating documentation gathering, intelligently routing submissions through appropriate channels like Availity or ePA partners, and monitoring policy changes. This reduces manual effort, minimizes errors, and aims to improve approval rates and turnaround times for your organization's revenue cycle.

Related coverage

Other mavenclad prior authorization by payer

Other mavenclad prior authorization by specialty

Ready to automate prior auth for this drug?

See how Klivira automates prior authorizations for your team.

Request a demo